RESEARCH ARTICLE

Cardiovascular phenotype of the Dmd\textsuperscript{mdx} rat – a suitable animal model for Duchenne muscular dystrophy

Petra Lujza Szabó\textsuperscript{1,}*+, Janine Ebner\textsuperscript{2,}*, Xaver Koenig\textsuperscript{2}, Ouafa Hamza\textsuperscript{1}, Simon Watzinger\textsuperscript{1}, Sandra Trojanek\textsuperscript{3}, Dietmar Abraham\textsuperscript{3}, Hannes Todt\textsuperscript{2}, Helmut Kubista\textsuperscript{2}, Klaus Schicker\textsuperscript{2}, Séverine Remy\textsuperscript{4}, Ignacio Anegon\textsuperscript{4}, Attila Kiss\textsuperscript{1,}\textsuperscript{1}, Bruno K. Podesser\textsuperscript{1} and Karlheinz Hilber\textsuperscript{2}

ABSTRACT

Besides skeletal muscle abnormalities, Duchenne muscular dystrophy (DMD) patients present with dilated cardiomyopathy development, which considerably contributes to morbidity and mortality. Because the mechanisms responsible for the cardiac complications in the context of DMD are largely unknown, evidence-based therapy approaches are still lacking. This has increased the need for basic research efforts into animal models for DMD. Here, we characterized in detail the cardiovascular abnormalities of Dmd\textsuperscript{mdx} rats, with the aim of determining the suitability of this recently established dystrophin-deficient small animal as a model for DMD.

Various methods were applied to compare cardiovascular properties between wild-type and Dmd\textsuperscript{mdx} rats, and to characterize the Dmd\textsuperscript{mdx} cardiomyopathy. These methods comprised echocardiography, invasive assessment of left ventricular hemodynamics, examination of adverse remodeling and endothelial cell inflammation, and evaluation of vascular function, employing wire myography. Finally, intracellular Ca\textsuperscript{2+} transient measurements, and recordings of currents through L-type Ca\textsuperscript{2+} channels were performed in isolated single ventricular cardiomyocytes. We found that, similar to respective observations in DMD patients, the hearts of Dmd\textsuperscript{mdx} rats show significantly impaired cardiac function, fibrosis and inflammation, consistent with the development of a dilated cardiomyopathy. Moreover, in Dmd\textsuperscript{mdx} rats, vascular endothelial function is impaired, which may relate to inflammation and oxidative stress, and Ca\textsuperscript{2+} handling in Dmd\textsuperscript{mdx} cardiomyocytes is abnormal.

These findings indicate that Dmd\textsuperscript{mdx} rats represent a promising small-animal model to elucidate mechanisms of cardiomyopathy development in the dystrophic heart, and to test mechanism-based therapies aiming to combat cardiovascular complications in DMD.

KEY WORDS: Muscular dystrophy, Remodeling, Cardiovascular dysfunction, Cardiomyocyte, Rat

INTRODUCTION

Duchenne muscular dystrophy (DMD), induced by mutations in the gene encoding for the intracellular protein dystrophin, is a severe X chromosome-linked illness characterized by progressive muscle weakness and degeneration. Besides the well-characterized skeletal muscle pathology, DMD is also associated with relevant cardiac complications (Shirokova and Niggli, 2013; Spurney, 2011). Among those, cardiac arrhythmias and the development of a dilated cardiomyopathy considerably contribute to the morbidity and mortality concomitant with the disease. The mechanisms responsible for the cardiac complications in the context of DMD are largely unknown, and this has increased the need for basic research efforts into animal models for DMD.

Among the used DMD animal models (McGreevy et al., 2015; Wells, 2018), the mdx mouse is the best known and the most widely used. It has a premature stop mutation in exon 23 of the murine Dmd gene, and consequently fails to translate functional full-length dystrophin (Sicinski et al., 1989). Although the mdx mouse is a useful genetic and biochemical model of DMD, it only partially mimics the human disease. Thus, in contrast to DMD patients, mdx mice only have a slightly shortened life span and do not show obvious clinical signs of muscular dystrophy (Grady et al., 1997; Gutpella et al., 2015). Further, cardiac abnormalities in mdx mice only develop late (Quinlan et al., 2004), and the cardiomyopathy is mild compared to that occurring in DMD patients (Grady et al., 1997; Janssen et al., 2005). This questions the suitability of this animal model for studying the cardiac disease phenotype.

In 2014, Larcher and colleagues described the development of dystrophin-deficient rats using transcription activator-like effector nucleases targeting exon 23 of the Dmd gene (Larcher et al., 2014). In these Dmd\textsuperscript{mdx} rats, cardiac muscle was affected by necrosis and fibrosis, and showed signs of progressive dilated cardiomyopathy. Echocardiography revealed significant concentric remodeling, and alteration of diastolic function. Based on these findings, the authors argued that the cardiac disease phenotype in Dmd\textsuperscript{mdx} rats closely mimics that observed in DMD patients, and that this animal model is potentially suitable for preclinical DMD research (Larcher et al., 2014). A weakness of the study – with an actual focus on skeletal muscle – is that the cardiac disease phenotype of Dmd\textsuperscript{mdx} rats was not characterized in great detail. For example, echocardiography was only performed on 3-month-old, but not older, rats. Moreover, the authors (Larcher et al., 2014) did not investigate potentially occurring vascular complications such as enhanced arterial stiffness (Ryan et al., 2017) and endothelial cell (EC) dysfunction (Mike et al., 1987), which may also contribute to the development of the cardiac disease phenotype in DMD patients. Finally, functional studies at the cellular level (i.e. on Dmd\textsuperscript{mdx} cardiomyocytes) have not yet been performed. Considering this lack of evidence, the aim of the present study was to provide a detailed characterization of the

0.000-0003-4652-1998

Handling Editor: Monica J. Justice

Received 8 October 2020; Accepted 23 December 2020
cardiac and vascular abnormalities in Dmdmdx rats both at the organ and cellular level. Our results suggest that Dmdmdx rats closely mimic the cardiovascular phenotype of DMD patients, and can thus be considered a promising small-animal model for the human disease.

RESULTS

Animal characteristics
Table 1 provides the summary of the animal characteristics. There was a significant difference in body weight between Dmdmdx (n=10) and wild-type (wt) (n=15) rats at the age of 9 months (Table 1). In addition, the total heart weight was decreased in Dmdmdx (n=10) versus wt (n=11) rats. Moreover, the wet lung weight, as well as the lung weight to body weight ratio, were markedly increased in the Dmdmdx (n=10) versus wt (n=11) rats at the age of 9 months, indicating cardiac dysfunction (Table 1).

Cardiac function and morphology
Left ventricular (LV) systolic and diastolic function, LV dimension and mean pulmonary artery pressure were assessed by transthoracic echocardiography (Fig. 1 and Table 2). We observed a slight, but significant reduction in ejection fraction (EF) in Dmdmdx rats compared to wt rats at the age of 3 months (Fig. 1A). Moreover, EF progressively declined in Dmdmdx rats compared to wt rats at the age of 7 and 9 months (Fig. 1A). Conversely, Dmdmdx rats showed increased LV end-systolic (LVEDD) and end-diastolic (LVEDD) diameters compared to wt rats, indicating progressive dilatation (Fig. 1B,C, respectively). At the age of 3 months, the Dmdmdx rats showed a tendency towards an increased ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/E' ratio), becoming significant at 7 and 9 months (Fig. 1D), reflecting elevated LV filling pressure and LV diastolic dysfunction. Furthermore, mean pulmonary artery pressure (mPAP) was significantly increased in the Dmdmdx rats compared to wt rats at the age of 7 and 9 months (Fig. 1E), indicating pulmonary hypertension.

LV hemodynamic function
To complement the echocardiography data, we measured LV hemodynamic parameters by an invasive method in Dmdmdx (n=10) and wt (n=8) rats at the age of 9 months. Dmdmdx rats exhibited reduced LV systolic function, as demonstrated by a significant decrease in the maximal LV systolic pressure (74±3 mmHg versus 95±4 mmHg in wt; P=0.001) and also significantly reduced rate of contraction [maximal rate of LV pressure development (dP/dtmax), 4458±344 mmHg/s versus 5956±288 mmHg/s in wt; P=0.004]. Simultaneously, LV end-diastolic pressure (LVEDP) was significantly increased in Dmdmdx rats compared to wt rats (4.8±0.5 mmHg versus 2.6±0.3 mmHg; P=0.0009). Similarly, the minimal rate of LV pressure fall (dP/dtmin) was significantly lower and revealed diastolic dysfunction in Dmdmdx rats (−3071±276 mmHg/s versus −4464±339 mmHg/s in wt; P=0.006).

Altered regulation of Ca2+ homeostasis, and oxidative and mechanical stress in dystrophic myocardium
To investigate whether Dmdmdx rats show altered gene expression associated with cardiomyocyte dysfunction and adverse remodeling, we performed quantitative reverse transcription PCR (RT-qPCR). Upregulation of NADPH oxidase (NOX) 2 and 4 in the myocardium causes cardiac dysfunction and fibrosis (Kuroda et al., 2010). Nos4 expression was significantly elevated in dystrophic rat hearts compared to wt rat hearts (Fig. 2A). Interestingly, we observed a significant upregulation of myocardin-related transcription factor A and B (MrTfa/b) expression in LV tissue samples from Dmdmdx rats compared to those from wt rats, in association with increases in collagen I and III expression (Fig. S1). In addition, sarcoplasmic reticulum (SR) Ca2+-ATPase 2a (SERCA2a; also known as Apa2a) mRNA expression was slightly increased in dystrophic compared to wt hearts (Fig. 2B). Next, we investigated phospholamban and sarcolipin, which are key regulators of SERCA activity, and found that, particularly, the expression of sarcolipin was markedly upregulated in Dmdmdx myocardium (Fig. 2B). The renin–angiotensin–aldosterone system (RAAS) was activated, and angiotensin-converting enzyme (ACEI) and angiotensin II type 1 receptor (AT1R; also known as Agtr1a) mRNA levels were significantly increased in dystrophic compared to wt hearts (Fig. 2C). Because dysregulation of neuronal NO synthase (nNOS; also known as Nos1) and utrophin are supposed to link to cardiac dysfunction (Wehling-Henricks et al., 2005) and compensate for dystrophin deficiency (Delfin et al., 2012), respectively, we measured the expression of both genes in LV tissue samples. There was no difference in nNOS mRNA levels (Fig. 2B); however, utrophin mRNA expression was ~17-fold higher in the Dmdmdx myocardium compared to wt myocardium (Fig. S2).

Cardiac fibrosis and inflammation
At 9 months of age, we evaluated histological cross sections of the heart at mid-papillary level (Fig. 3A). The results showed that the amount of fibrosis (blue in Fig. 3A) was significantly increased in both the left ventricle and right ventricle in Dmdmdx compared to wt rats (Fig. 3B). In addition, the RT-qPCR results showed a marked increase in collagen I and III mRNA expression in LV tissue samples of Dmdmdx rats (Fig. 3C). Furthermore, staining for CD68 + macrophages (Fig. 3D) and tenascin-C (TN-C) (Fig. 3E) was enhanced in Dmdmdx rats compared to wt rats.

Vascular endothelial function and contractility
Acetylcholine (ACH)-induced vasorelaxation, indicative of endothelium-dependent vasodilation, and sodium nitroprusside (SNP)-induced vasorelaxation, indicative of endothelium-independent vasodilation, were assessed in isolated abdominal aortic segments from Dmdmdx and wt rats at 9 months of age. In phenylephrine (PE)-preconstricted aortic rings, the relaxation in response to ACh was significantly blunted in Dmdmdx rats (Fig. 4A), with decreased sensitivity (logEC50, −7.19 versus −7.52 in wt; P<0.01), suggesting impaired endothelial-dependent vasorelaxation. In addition, endothelium-independent relaxation induced by SNP showed decreased sensitivity (logEC50, −8.163 versus −7.792 in wt; P<0.01; Fig. 4B), but similar maximal response, between the two groups.
Expression of inflammatory markers in lung ECs

To further elucidate the underlying mechanisms responsible for endothelial dysfunction, CD31+ ECs were isolated from the lungs. ECs isolated from Dmdmdx rat lungs showed higher mRNA expression of pro-inflammatory marker interleukin 1 beta (Il1b), and also of mechanical stress-related molecules, such as Mrtfa and Mrtfb (Fig. 4C). Moreover, superoxide dismutase 1 (Sod1) mRNA expression was significantly elevated in ECs isolated from Dmdmdx rats compared to those from wt rats. In addition, there was a trend toward increased Nox4 mRNA expression in Dmdmdx compared to wt ECs (Fig. 4C). Elevated levels of the EC adhesion molecule vascular cell adhesion molecule 1 (Vcam1) in ECs from Dmdmdx rats further indicated an imbalance in vascular function in this animal model of DMD (Fig. 4C).

ACE activity in kidney, lung and LV tissue samples

To evaluate potential factors contributing to LV dilation and myocardial fibrosis, we assessed ACE activity in kidney, lung and LV tissue samples from Dmdmdx and wt rats at 9 months of age (Fig. 5A-C). ACE activity was only increased significantly in kidney samples from Dmdmdx rats in comparison to those from wt rats (Fig. 5A).

Intracellular Ca2+ transients

Impaired functional properties in the dystrophic heart may arise from abnormalities at the cardiomyocyte level, e.g. impaired cellular Ca2+ handling and consequently attenuated contractility. To test this hypothesis, we recorded intracellular Ca2+ transients in ventricular cardiomyocytes, which were derived from wt and dystrophic Dmdmdx rats (Fig. 6A,B). Fig. 6C shows that the amplitude of electrically stimulated Ca2+ transients was significantly diminished in Dmdmdx compared to wt cells. In addition, signal decay in Dmdmdx myocytes was slowed, as indicated by significantly increased time constant (τ) values (Fig. 6D).

As a next step, we elicited Ca2+ transients by means of caffeine (20 mM) application (Fig. 6E-H), and compared peak amplitudes (Fig. 6G) and signal decay (Fig. 6H) between wt and Dmdmdx myocytes. Similar to what we had observed with electrically induced Ca2+ transients, the amplitude of caffeine-induced Ca2+ transients was significantly diminished in Dmdmdx compared to wt cells (Fig. 6G). Further, Ca2+ signal decay during continuous caffeine application in Dmdmdx myocytes was slowed compared to that in wt myocytes (Fig. 6H).

Li et al. (2014) reported that cardiac beta-adrenergic responses were attenuated in dystrophic mdx mice compared to wt mice. Here, we tested whether cardiac beta-adrenergic responsiveness was also impaired in the Dmdmdx rat model, by comparing isoprenaline effects on electrically stimulated Ca2+ transients in wt and Dmdmdx myocytes. Fig. 7A shows that external application of 100 nM isoprenaline led to a prominent increase in Ca2+ transient amplitude both in wt and Dmdmdx cells. Similar transient peak amplitudes were reached under isoprenaline stimulation in both cell types.

Nitric oxide (NO), generated by nNOS activity, has an inhibitory effect and significantly diminishes Ca2+ transients (Burger et al., 2009; Sears et al., 2003). Here, we tested the stimulatory effects of the selective cell permeable nNOS inhibitor vinyl-L-NIO (hydrochloride) (L-VNIO; Cayman Chemical, CAY-80330-5) on Ca2+ transients recorded from wt and Dmdmdx myocytes. We found that external application of 100 µM L-VNIO increased the transient peak amplitudes in wt and dystrophin-deficient cells (Fig. 7B). As described above for isoprenaline stimulation, L-VNIO application also resulted in similar Ca2+ transient peak amplitude values in both cell types.

Ca2+,1.2 protein expression and L-type Ca2+ channel currents

To study potential abnormalities in Ca2+,1.2 Ca2+ channel expression and localization in Dmdmdx ventricular cardiomyocytes, we performed immunofluorescence studies using an antibody specific

Table 2. Transthoracic echocardiography parameters

|          | 3 months |          | 7 months |          | 9 months |
|----------|----------|----------|----------|----------|----------|
|          | wt       | Dmdmdx   | wt       | Dmdmdx   | wt       | Dmdmdx   |
| LV EF (%)| 82±2     | 76±4*    | 81±2     | 71±4***  | 81±6     | 66±6***  |
| LVEDD (mm)| 4±1±0.6 | 5.1±0.6**| 4.8±0.2  | 5.8±0.4***| 4.8±0.2  | 6.0±0.5***|
| LVEF (%) | 7.4±0.34 | 8.3±0.4* | 8.5±0.2  | 9.0±0.3***| 8.7±0.2  | 9.4±0.3***|
| E/E ratio| 13.4±4.4 | 15.6±8.4 | 10.5±2.1 | 20.2±6.5**| 11.4±1.9 | 19.1±5.3**|
| mPAP     | 24±5     | 21±6     | 18±4     | 24.3±2   | 19±4     | 28±5**   |
| n        | 8        | 7        | 7        | 8        | 7        | 7        |

LV EF, left ventricular (LV) ejection fraction; LVEDD, LV end-systolic diameter; LVEF, LV end-diastolic diameter; E/E ratio, ratio between early mitral inflow velocity and mitral annular early diastolic velocity; mPAP, mean pulmonary arterial pressure. Data are expressed as mean±s.d.; *P<0.05, **P<0.01, ***P<0.001, using unpaired Student’s t-test.
for the Ca$_{1.2}$ alpha1 subunit (also known as CACNA1C). Fig. 8A compares typical examples of Ca$_{1.2}$ immunostaining in wt and Dmdmdx myocytes. Cross-striations, representing T-tubular localization of Cav1.2 Ca$^{2+}$ channels, can be observed in wt and dystrophin-deficient cells. Similar staining patterns, with comparable signal intensities under identical excitation conditions and microscope settings, were obtained in all the studied wt and Dmdmdx myocytes, which originated from two wt and two dystrophic rats, respectively.

In a final set of experiments, we tested potential abnormalities in Ca$^{2+}$ channel functional properties. Therefore, we recorded currents through L-type Ca$^{2+}$ channels in wt and Dmdmdx cardiomyocytes. Fig. 8B-D show that the currents in wt and dystrophin-deficient cells were basically similar. Thus, first, no significant difference existed between the current density-voltage relationships of wt and Dmdmdx myocytes (Fig. 8C). Second, current decay after channel activation at various membrane potentials, representing the kinetics of macroscopic Ca$^{2+}$ channel inactivation, was similar in wt and dystrophin-deficient cells (Fig. 8D). A statistically significant difference (a faster decay in Dmdmdx versus wt; *P<0.05; **P<0.01; ***P<0.001, using unpaired Student’s t-test) only existed at a potential of +30 mV.

Fig. 3. Histopathological evaluation of cardiac fibrosis and inflammation from wt and Dmdmdx rats at 9 months of age. (A) Representative Masson-Goldner staining of LV sections from wt and Dmdmdx rats at 9 months of age. Blue indicates fibrosis. (B) Quantitative data showing the extent of LV and right ventricular fibrosis. (C) Collagen I and III mRNA expression in myocardium. (D,E) High-magnification photomicrographs show increased levels of CD68$^+$ macrophages (D) and tenascin-C (E) expression in Dmdmdx rat hearts compared to wt rat hearts. Scale bars: 1 mm (overview) and 50 μm (enlarged sections). Data are expressed as mean ±s.d.; n=7 wt and n=7 Dmdmdx in histology; n=11 wt and n=10 Dmdmdx in RT-qPCR. *P<0.05, ***P<0.001, using unpaired Student’s t-test.
DISCUSSION

Here, for the first time, we provide a detailed characterization of the cardiovascular abnormalities of Dmdmdx rats (Larcher et al., 2014). Our study also reveals potential signaling mechanisms that may play a role in cardiomyocyte and EC dysfunction, as well as in adverse LV remodeling, in the dystrophic heart. In summary, we found that the hearts of Dmdmdx rats show significant and progressive diastolic and systolic dysfunction, as well as cardiac fibrosis and inflammation, consistent with the development of a pronounced dilated cardiomyopathy. Moreover, in Dmdmdx rats, vascular endothelial function is impaired, and Ca\(^{2+}\) handling in Dmdmdx cardiomyocytes is abnormal.

Comparison of cardiac function between Dmdmdx rats and DMD patients

In contrast to Larcher et al. (2014), in the present study, we went further and investigated LV remodeling and cardiac function beyond the age of 3 months; namely, after 7 and 9 months. Our data at 3 months confirmed the results of Larcher et al. (2014), but we were only able to demonstrate a trend toward diastolic dysfunction. However, we found a significant reduction in EF at an early stage (3 months). E/E′ ratio, as a surrogate marker of diastolic function, was significantly increased in Dmdmdx rats compared to wt rats at 7 and 9 months, confirming the diastolic dysfunction in Dmdmdx rats. Echocardiography data were supported by invasive LV pressure measurements at sacrifice (9 months). Accordingly, Dmdmdx rats showed lower LV maximum pressure, dP/dtmax and dP/dtmin. In addition, there was a significant difference in LVEDP between the two groups.

The rapid and progressive dilatation and contractile dysfunction in Dmdmdx rats is in alignment with the cardiac complications in DMD patients, as cardiac involvement becomes more prominent with age (Nigro et al., 1990). It has been also shown that DMD and Becker muscular dystrophy (BMD) patients express abnormally high levels of utrophin (Taylor et al., 1997), similar to what we observed in LV tissue samples of Dmdmdx compared to wt rats (Fig. S2). The level of this protein is indicating compensatory mechanisms, as utrophin can partially substitute dystrophin. Notably, pulmonary hypertension is a typical malformation of patients affected by DMD owing to respiratory failure. This underlines the potential of Dmdmdx rats to study the dystrophic disease phenotype (Yotsukura et al., 1991). Of importance, LV function in patients with DMD declined over time, independent of non-invasive positive pressure ventilation use (James et al., 2020).

Comparison of cardiac morphology, inflammation and neurohumoral activation between Dmdmdx rats and DMD patients

Dilated cardiomyopathy is typically observed in DMD patients and characterized by LV dilatation and excessive myocardial fibrosis.
In line with that, Dmdmdx rats exhibited an enlargement of LVESD (at 3, 7 and 9 months) and LVEDD (at 3, 7 and 9 months) compared to wt animals. Previous studies demonstrated that an increase in LV dilatation and concomitant reduced systolic function increase the risk of ventricular arrhythmia (e.g. Finsterer et al., 2010), confirming the suitability of the Dmdmdx rat model for studying the molecular and cellular mechanisms of electrophysiological abnormalities in DMD.

Patients affected by DMD develop a progressive dilated cardiomyopathy, characterized by inflammatory cell infiltration, followed by necrosis and excessive replacement with cardiac fibrosis (Olivieri et al., 2016). The fibrotic region gradually becomes thinner and loses contractility, resulting in dilated cardiomyopathy (Kaspar et al., 2009). More recently, Ouisse et al. (2019) demonstrated that CD68+ positive cell staining was markedly increased in cardiac tissue of Dmdmdx rats at the age of 12 weeks. In line with that, our study confirms a large amount of fibrosis and CD68+ macrophage infiltration in both left and right ventricles in Dmdmdx rats at the age of 9 months. Collectively, these data suggest that targeting inflammation and cardiac fibrosis are potential approaches to delay and limit cardiac dysfunction in DMD patients.

Accordingly, a recent randomized clinical trial has demonstrated that drugs inhibiting the RAAS, including ACE inhibitors, significantly reduce the progression of myocardial fibrosis in patients...
with DMD or BMD (Silva et al., 2017), suggesting a deleterious role of ACE in DMD-related myocardial fibrosis. Therefore, we measured ACE activity in various organs and AT1R expression in LV tissue. We first demonstrated that ACE activity was significantly increased in kidney tissue from Dmdmdx rats, but was not altered in lungs and LV tissue samples. However, AT1R expression was significantly increased in LV tissue, which may support the benefit of using ACE inhibitors or AT1R blockers to delay cardiac dysfunction and concomitant fibrosis in DMD patients. Besides, ACE produces the potent vasoconstrictor angiotensin II, which is known to be a key mediator in the development of pulmonary hypertension, vascular remodeling and endothelial dysfunction (Cohn, 2000). Additionally, a mechanistic link between angiotensin II and TN-C has recently been demonstrated (Santer et al., 2020). Further, TN-C knockout mice develop less LV dilatation and fibrosis under chronic pressure overload condition than wt mice (Podesser et al., 2018). In line with that, upregulation of TN-C in serum or cardiac tissue predicted worse outcome in patients with myocardial infarction (Sato et al., 2006) and dilated cardiomyopathy (Yokokawa et al., 2016). In the present study, we were able to demonstrate, for the first time, that cardiac TN-C expression was markedly increased in Dmdmdx rats compared to wt rats, suggesting its pathophysiological role in LV dilatation and fibrosis. Of importance, a previous clinical study reported positive interaction between LV dilatation and TN-C levels in DMD and Emery-Dreifuss muscular dystrophy patients (Niebroj-Dobosz et al., 2011).

Besides the evidence-based pro-fibrotic effects of RAAS upregulation in DMD, our study results suggest that MRTFA may be a novel potential mediator, as well as target, in cardiac fibrosis in DMD. Previous studies demonstrated the role of MRTFA in cardiac fibrosis (Osmanagic-Myers et al., 2019; Sharma et al., 2017). Accordingly, Mrtfa upregulation in LV tissue samples from Dmdmdx rats was associated and correlated with collagen I and III expression (Fig. S1).
long benefit in DMD patients, underlining the pathophysiological importance and potential target of vascular endothelium in DMD-associated cardiovascular abnormalities.

**Correlation between Dmdmdx rat ‘organ’ and ‘cellular’ abnormalities**

Abnormal Ca\(^{2+}\) transients are a pivotal feature of failing hearts: typically, Ca\(^{2+}\) transients in ventricular cardiomyocytes from heart failure patients are smaller, and their duration is prolonged (Balke and Shorofsky, 1998; Benitah et al., 2003; Beuckelmann et al., 1992). Importantly, these alterations at the cellular (cardiomyocyte) level are causative for impaired cardiac function (Balke and Shorofsky, 1998; Gambardella et al., 2018; Pieske et al., 1995). Thus, reduced Ca\(^{2+}\) release from the SR impairs cardiomyocyte contractility, and consequently systolic function, whereas diminished Ca\(^{2+}\) removal from the cytosol after SR Ca\(^{2+}\) release increases diastolic dysfunction (Balke and Shorofsky, 1998; Gambardella et al., 2018; Hoshijima et al., 2006). Based on these facts, we propose that the functional impairments of the heart in Dmdmdx rats reported herein can at least partly be explained by the altered Ca\(^{2+}\) transient properties in Dmdmdx ventricular cardiomyocytes. In particular, the reduced Ca\(^{2+}\) transient amplitude in dystrophin-deficient myocytes may contribute to impaired systolic function in the Dmdmdx heart, and the slowed transient decay in Dmdmdx cells is consistent with diastolic dysfunction in the dystrophic heart. Finally, it should also be mentioned that abnormal Ca\(^{2+}\) transients in dystrophin-deficient cardiomyocytes predispose the dystrophic heart to cardiac arrhythmias (Fauconnier et al., 2010).

**Potential mechanisms underlying abnormal Ca\(^{2+}\) handling in Dmdmdx cardiomyocytes**

Impaired Ca\(^{2+}\) transients, but at the same time normal L-type Ca\(^{2+}\) channel expression and functional properties in Dmdmdx cardiomyocytes (see above), exclude Ca\(_{1,2}\) Ca\(^{2+}\) channel dysfunction as a triggering mechanism for abnormal Ca\(^{2+}\) release. Decreased electrically evoked Ca\(^{2+}\) transient amplitudes, suggesting reduced Ca\(^{2+}\) release from the SR via ryanodine receptors, in dystrophin-deficient myocytes may alternatively arise from disturbed ryanodine receptor function in the SR membrane and/or a diminished SR Ca\(^{2+}\) load. Our caffeine experiments provide support for the latter mechanism – reduced Ca\(^{2+}\) content of the SR, potentially caused by leaky ryanodine receptors, as in dystrophin-deficient murine mdx cardiomyocytes (Fauconnier et al., 2010; Gonzalez et al., 2014; Shirokova and Niggli, 2013). Thus, caffeine-induced Ca\(^{2+}\) transient amplitude, a measure for SR Ca\(^{2+}\) load (Williams and Allen, 2007), was significantly decreased in Dmdmdx compared to wt cardiomyocytes. Finally, our data also exclude impaired Ca\(^{2+}\) channel inactivation as cause for the prolonged electrically evoked Ca\(^{2+}\) transient duration observed in Dmdmdx cardiomyocytes. Consequently, removal of Ca\(^{2+}\) from the cytosol after release, reflected by decay of the Ca\(^{2+}\) signal, must be attenuated by a direct mechanism such as impaired SERCA function. In accordance, SERCA activity was shown to be reduced in dystrophin-deficient mouse hearts (Voit et al., 2017; Williams and Allen, 2007). An abnormally decreased rate of Ca\(^{2+}\) uptake by the SR was also found in ventricular cardiomyocytes from patients with dilated cardiomyopathy (Beuckelmann et al., 1995).

The reason for reduced SERCA activity in dystrophic rat cardiomyocytes remains unknown. Our RT-qPCR studies point to a role of sarcoplasm. This protein is a potent SERCA inhibitor (Voit et al., 2017), and its expression is massively upregulated in Dmdmdx rat hearts (Fig. 2B). This finding is in line with abnormally elevated sarcoplasm in the muscle of DMD patients and mouse models of the disease (Voit et al., 2017). Most interestingly in this context, in recent studies, both a single systemic delivery of SERCA2a with adeno-associated virus (Wasala et al., 2020) and sarcoplasm deletion (Voit et al., 2017) improved Ca\(^{2+}\) recycling and provided considerable benefits in mouse models of DMD.

Finally, our study additionally suggests that, at the cardiomyocyte level, the regulation of Ca\(^{2+}\) handling via the beta-adrenergic pathway and via nNOS activity is not impaired by dystrophin deficiency.

**Comparison of cytosolic Ca\(^{2+}\) transient properties in rat Dmdmdx and human DMD cardiomyocytes**

Here, we report decreased electrically evoked Ca\(^{2+}\) transient amplitudes and a prolonged Ca\(^{2+}\) transient duration (slowed signal decay) in dystrophin-deficient Dmdmdx compared to wt cardiomyocytes. The latter abnormality was also observed in human induced pluripotent stem cell (iPSC)-derived cardiomyocytes from a DMD patient (Guan et al., 2014). Also, cardiomyocytes isolated from the ventricular myocardium of dilated cardiomyopathy patients showed comparable abnormalities in electrically evoked Ca\(^{2+}\) transients, as we observed in Dmdmdx myocytes: a decreased Ca\(^{2+}\) transient amplitude and a slowed transient decay compared to myocytes derived from healthy donor ventricles (Beuckelmann et al., 1992, 1995). Finally, our finding of decreased caffeine-evoked Ca\(^{2+}\) transient amplitudes in Dmdmdx compared to wt rat myocytes accords with abnormally small caffeine-induced Ca\(^{2+}\) transients in myocytes derived from patients with terminal heart failure owing to dilated cardiomyopathy or ischemic heart disease (Lindner et al., 1998). Together, these comparisons suggest that, as far as Ca\(^{2+}\) transient properties in ventricular cardiomyocytes are concerned, the Dmdmdx rat model well resembles the situation observed in diseased (DMD, dilated cardiomyopathy) human myocytes.

**Comparison of L-type Ca\(^{2+}\) channel properties in rat Dmdmdx and human DMD cardiomyocytes**

Dystrophin-deficient Dmdmdx rat myocytes show Ca\(^{2+}\) channel properties very similar to those of wt cells. In line with these rat model data, iPSC-derived cardiomyocytes from DMD patients had similar Ca\(^{2+}\) current densities to myocytes derived from a healthy control individual (E. Jimenez Vazquez, University of Michigan, personal communication). Further, cardiomyocytes isolated from the ventricular myocardium of dilated cardiomyopathy patients had comparable Ca\(^{2+}\) current densities to myocytes derived from healthy donor ventricles (Beuckelmann et al., 1992). This suggests that, regarding Ca\(^{2+}\) current properties in ventricular cardiomyocytes, the Dmdmdx rat model resembles the situation observed in human disease.

**Limitations**

Certain limitations of the study have to be acknowledged. First, we only measured cardiac fibrosis, vascular function and cardiomyocyte properties at a defined age of 9 months. We therefore do not provide information about disease development. Second, we only measured markers related to cardiac remodeling, Ca\(^{2+}\) handling in cardiomyocytes and oxidative stress in ECs at mRNA level. Validation at protein level should be part of future studies.

**Conclusion**

In conclusion, we were able to show that Dmdmdx rats represent a promising small-animal model to elucidate mechanisms of cardiomyopathy development in the dystrophic heart. Accordingly, Dmdmdx rats show significantly impaired LV hemodynamic function and adverse remodeling with concomitant cardiac fibrosis and inflammation. Furthermore, in Dmdmdx rats, vascular endothelial...
function is impaired, which may be related to inflammation and oxidative stress marker upregulation. At the cellular level, Ca2+ handling in Dmdmdx cardiomyocytes is abnormal. Collectively, in contrast to the classical mdx mouse model, the cardiovascular phenotype of Dmdmdx rats is developing quickly, strong and very similar to that observed in DMD patients. We therefore believe that Dmdmdx rats represent a suitable small-animal model to test novel therapies aiming to combat cardiovascular complications in DMD and other forms of dilated cardiomyopathies.

MATERIALS AND METHODS

Animals
Male Dmdmdx (n=14) and wt littermate control (n=15) Sprague Dawley rats were from INSERM-CRT1 UMR 1064. Genotyping of the rats was performed using standard PCR assay as described previously (Larcher et al., 2014). The experimental protocol was approved by the regional Ethics Committee for Laboratory Animal Experiments at the Medical University of Vienna and the Austrian Ministry of Science Research and Economy (BMWFV-66.009/0175-WF-V/3b/2015). All procedures conform to the guidelines from Animal Research: Reporting of In Vivo Experiments (ARRIVE) and Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.

Transhormacjodynamic assessment
Transhormacjodynamic assessment was performed as described previously (Pilz et al., 2019). Briefly, rats were anesthetized (isoflurane 2-3%) and echocardiography was performed using a Vivid 7 system (GE Healthcare, USA) equipped with an 11.5 MHz 10S sector transducer. LV EF, LVEDD and LVEDV were evaluated at midpapillary short-axis view. Tissue Doppler of the septal mitral annulus as well as the mitral flow were obtained in a four-chamber view to evaluate LV filling pressure. The force of the ventricular systolic pressure axis, pulse wave Doppler flow tracings from the pulmonary artery were obtained, and pulmonary artery acceleration time (% PAAT) was measured as the time from onset of the flow to the peak flow velocity. mPAP was then calculated using a regression equation validated in rats: mPAP=58.7-(1.21×PAAT) (Jurioniene et al., 2010).

Assessment of vascular reactivity in isolated aortic rings
Assessment of vascular reactivity in isolated aortic rings
Vascular function was assessed in isolated aortic rings as described previously (Osmanagic-Myers et al., 2019). Briefly, rats abdominal aorta (at the age of 9 months) was dissected and placed into cold and oxygenated (5% CO2; and 95% O2) Krebs buffer containing 119 mmol/l NaCl, 4.7 mmol/l KCl, 2.5 mmol/l CaCl2, 1.17 mmol/l MgSO4, 20 mmol/l NaHCO3, 1.18 mmol/l KH2PO4, 0.027 mmol/l EDTA and 10.5 mmol/l glucose. The segments of the aorta were gently perfused to remove all the remaining blood from the lumen and cleaned of the connective tissue around the vessel. Aortic rings (2-3 mm) were mounted onto a multichamber isometric myograph system (Model 620 M, Danish Myo Technology, Aarhus, Denmark). The organ chambers of the myograph were filled with heated (37°C) and oxygenated Krebs solution, and the individual chambers were further heated and bubbled during the whole procedure. Segments were allowed to equilibrate for 45 min and resting tension was continuously adjusted during this period as described previously (Szekeres et al., 2015). Reference contractions were elicited by hyperkalemic (124 mM, KCl) solution. Precontraction of the segments was performed by PE (1 nM-10 µM; Sigma-Aldrich). Endothelial-dependent and -independent relaxation was tested with ACh (1 nM-10 µM; a nitric oxide-dependent vasodilator; Sigma-Aldrich) and SNP (0.1 nM-1 µM; a nitric oxide-independent vasodilator; Merck), respectively. The data were continuously recorded using the software program LabChart Pro (ADInstruments).

Isolation of lung ECs
Isolation of lung ECs
Lungs were removed and placed into ice-cold PBS before being finely minced. The fragments were collected in pre-warmed (37°C) 2 mg/ml Collagenase-PBS solution (Collagenase Type IV from Gibco) and incubated for 45 min at 37°C. The mixture was passed through a 70-µm cell strainer. The red blood cells were eliminated by red blood cell lysis buffer (Roche). Mouse anti-rat CD31 antibody (BD Pharmingen) was incubated with magnetic beads coated with pan anti-mouse IgG (Dynabeads™, Invitrogen) on a rotator plate at 4°C overnight (100 μl magnetic beads and 10 μl anti-rat CD31 antibody in 4 ml 0.1% PBS-BSA buffer was calculated for one rat lung). The rat lung cell suspension was incubated together with the magnetic beads on a rotator plate for 20 min at room temperature and then the CD31+ cells were separated by a magnetic particle concentrator (Dynabeads™, Invitrogen) and the individual chambers were further heated and bubbled during the whole procedure. Segments were allowed to equilibrate for 45 min and resting tension was continuously adjusted during this period as described previously (Szekeres et al., 2015). Reference contractions were elicited by hyperkalemic (124 mM, KCl) solution. Precontraction of the segments was performed by PE (1 nM-10 µM; Sigma-Aldrich). Endothelial-dependent and -independent relaxation was tested with ACh (1 nM-10 µM; a nitric oxide-dependent vasodilator; Sigma-Aldrich) and SNP (0.1 nM-1 µM; a nitric oxide-independent vasodilator; Merck), respectively. The data were continuously recorded using the software program LabChart Pro (ADInstruments).

ACE activity measurement
ACE activity measurement
ACE activity in heart, lung and kidney tissue samples was measured as originally described by Carmona et al. (2006) and modified by Fagyas et al. (2014). Briefly, tissue samples were weighed and a proportional amount of 100 mM tris(hydroxymethyl)aminomethane hydrochloride (TRIS) buffer (pH 7.0) added then homogenized. The tissue homogenates were centrifuged at 15,000 g for 5 min, and the protein concentration of the supernatant was determined by a Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific) using a TECAN (SparkControl Magellan V.2.2) plate reader. ACE activity was determined with an artificial substrate (Abz-FRKDeP-OH (synthesized by Peptide 2.0, Champaign, IL, USA)) in a reaction mixture containing 6 µl of 1 mg/ml tissue homogenates in 35-fold dilution in 100 mM TRIS buffer, 50 mM NaCl, 10 µM ZnCl2. Measurements were performed in 96-well plates (Greiner-Bio One) at 37°C. The fluorescence intensity change was detected by a TECAN (SparkControl Magellan V.2.2) plate reader (excitation, 340 nm; emission, 405 nm). The changes in fluorescence intensity were detected in kinetic loops, at 1-min
intervals for at least 30 min and the intensity values were plotted as a function of reaction time. The fluorescence intensity values were fitted by a linear regression (GraphPad Software, San Diego, CA, USA), and the fit with the data was accepted only when $r^2$ was >0.9. ACE activity was calculated by the following equation: activity=(S/k)−D/P, where $S$ is the rate of the increase in fluorescence intensity (1/min), $k$ is the change in fluorescence intensity during the complete cleavage of 1 pmol Abz-FK(R)DpP-OPH substrate, $D$ is the dilution of the sample, and $P$ is the mg/ml protein concentration; 1 unit (U) means 1 pmol substrate cleavage in 1 min by 1 mg of protein.

**RT-qPCR**

Total RNA and miRNA were extracted and isolated using a mirNeasy Mini Kit (Qiagen, Hilden, Germany) from rat LV tissue and lung EC cell suspension according to the protocol provided. Briefly, QIAzol buffer was added to each tube containing either 50 mg myocardium for tissue homogenization using a tissue rupture (Qiagen) or lung EC cell suspension. Chloroform was added, and, after centrifugation, a volume of absolute ethanol was added to the upper phase and transferred to a mirNeasy Mini spin column. After several washing steps, total RNA was obtained after adding 30 μl nucleoside-free water. RNA concentration was measured using NanoQuant plateTM and TECAN plate reader (SparkControl Magellan V2.2). cDNA was prepared using a Quantitect reverse transcription kit (Qiagen), according to the manufacturer’s instructions. After cDNA preparation, quantitative PCR was performed using a Quantitect SYBR Green PCR kit (Qiagen). Samples were analyzed in duplicate using Rotor-Gene Q (Qiagen). Relative gene expression (listed in Table S1) was calculated by 2−ΔΔCt method.

**Isolation of ventricular cardiomyocytes**

Male wt and Dmdmdx rats (n=4 wt and n=4 Dmdmdx animals) at the age of 9 months were killed by cervical dislocation. Cardiomyocytes were isolated from the ventricles of their hearts using a Langendorff setup according to the myocyte isolation procedure from mice described in our previous work (Koenig et al., 2011).

**Intracellular Ca2+ transient measurements**

Ca2+ transients were recorded from isolated rat ventricular wt and Dmdmdx cardiomyocytes at room temperature following the protocol described in detail in our recently published study (Rubi et al., 2018). In brief, myocytes pre-loaded with the cell membrane-permeable Ca2+-sensitive fluorescent dye Fluo-4 AM (Thermo Fisher Scientific, Vienna, Austria) were bathed in an extracellular solution containing 140 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 5 mM glucose, pH adjusted to 7.4 with NaOH. Electrical stimulation via platinum electrodes in the bath was performed at 0.2 Hz in order to elicit Ca2+ transients. To elicit caffeine-induced SR Ca2+ release, bath solution containing 20 mM caffeine was applied via an OctaFlow II perfusion system (ALA Scientific Instruments, Novato, CA, USA), and had resistances between 1 MΩ and 2 MΩ when filled with pipette solution (see below). Data acquisition was performed with pClamp 11.0 software (Axon Instruments) through a 16-bit A-D/D-A interface (Digidata 1440; Axon Instruments). Data were low-pass filtered with 2 kHz (3 dB) and digitized at 5 kHz. Leak currents and capacity transients were subtracted using a P/4 protocol. Data were analyzed with Clampfit 10.7 (Axon Instruments) and Prism 5.04 (GraphPad Software) software. For rapid solution exchange, a DAD-8-VC superfusion system (ALA Scientific Instruments, Westbury, NY, USA) was used. The bath solution contained 10 mM BaCl2, 145 mM TEA-Cl, 2 mM Mg-ATP, pH 7.4 adjusted with tetraethylenammonium hydroxide solution. The pipette solution consisted of 145 mM Cs-aspartate, 2 mM MgCl2, 10 mM HEPES, 0.1 mM Cs-EGTA, 2 mM Mg-ATP, pH 7.4 adjusted with CsOH. The currents were elicited from a holding potential of −80 mV by depolarizing voltage steps up to +50 mV. For the determination of current density-voltage relations, the current amplitudes at various voltages were measured and then divided by the cell capacitance to obtain current densities. The values were then plotted against the respective test pulse potentials. The kinetics of barium current inactivation was derived from single exponential fits of the current decay after channel activation at different membrane potentials, and expressed as t-values.

**Statistical analyses**

Data are expressed as means±s.d. The echocardiographic data were compared by unpaired two-tailed Student’s t-test between groups at defined age (3, 7 and 9 months). Vascular relaxation in response to ACh or SNP was expressed as a percentage of contraction induced by PE. The statistical comparison between the relaxation and contraction responses was assessed using two-way analysis of variance (ANOVA) for repeated measures. Statistical comparisons between wt and Dmdmdx cardiac and EC gene expression values, and between wt and Dmdmdx cardiomyocytes, were made using an unpaired two-tailed Student’s t-test. $P<0.05$ was considered significant.

**Acknowledgements**

We thank Milat Inci (Ludwig Boltzmann Institute for Cardiovascular Research at Center for Biomedical Research, Medical University of Vienna, Vienna, Austria) for helping to establish the ACE activity assay in our laboratory.

**Funding**

This work was supported by the Austrian Science Fund (P30234-B27 to K.H.) and the Ludwig Boltzmann Society (REM 2017-20 to B.K.P.).
Kaspar, R. W., Allen, H. D. and Montanaro, F. (2009). Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J. Am. Acad. Nurse Pract. 21, 241-249. doi:10.1111/j.1745-7599.2009.00404.x

Koene, R. X., Dysek, S., Kimbacher, S., Mike, A. K., Cervenka, R., Lukacs, P., Nagl, K., Dang, X. B., Todt, H., Bittner, R. E. et al. (2011). Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart. PLoS ONE 6, e20300. doi:10.1371/journal.pone.0020300

Kuroda, J., Ago, T., Matusushima, S., Zhai, P., Schneider, M. D. and Sadoshima, J. (2011). NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl. Acad. Sci. USA 107, 15565-15570. doi:10.1073/pnas.1021781107

Larcher, T., Lafoux, A., Tessler, L., Remy, S., Thepenier, V., Francois, V., Le Guen, C., Gobuin, H., Dutilleul, M., Guigand, L. et al. (2014). Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE 9, e110371. doi:10.1371/journal.pone.0110371

Li, Y., Zhang, S., Zhang, X., Li, J., Al, X., Zhang, L., Yu, D., Ge, S., Peng, Y. and Chen, X. (2014). Blunted cardiac beta-adrenergic response as an early indication of cardiac dysfunction in Duchenne muscular dystrophy. Cardiovasc. Res. 103, 60-71. doi:10.1093/eurheartj/evu351

Lindner, M., Erdmann, E. and Beuckelmann, D. J. (1998). Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. J. Mol. Cell. Cardiol. 30, 743-749. doi:10.1006/jmcc.1997.0626

McGreedy, J. W., Hakim, C. H., McIntosh, M. A. and Duan, D. (2015). Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. J. Cell. Mol. Med. 19, 215-213. doi:10.1111/jcmm.12654

Mike, T., Sugino, S., Ohtani, T., Taku, K. and Yoshikoa, K. (1987). Vascular endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the preclinical stage. J. Neurol. Sci. 82, 67-80. doi:10.1016/0022-510X(87)90007-4

Nelson, M. D., Rader, F., Tang, X., Tavvey, J., Nelson, S. F., Miceli, M. C., Elashoff, R. M., Sweeney, H. L. and Victor, R. G. (2014). PDE6 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82, 2085-2091. doi:10.1212/WNL.0000000000000498

Niebro-Dobosz, I., Madej-Palczyc, A., Marchel, M., Sokolowska, B. and Hausmann-Prus-Petruszewicz, I. (2011). Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clin. Chim. Acta 412, 1533-1538. doi:10.1016/j.cca.2011.04.033

Nigro, G., Comi, L. I., Politano, L. and Bain, R. J. I. (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 271-277. doi:10.1016/0167-5273(90)90082-8

Nolte, J. K., Kellman, P., McCarter, R. J., Cross, R. R., Hansen, M. S. and Spurney, C. F. (2016). Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy. J. Cardiovasc. Magn. Reson. 18, 72. doi:10.1186/s12968-016-0292-8

Osmanagic-Myers, S., Kiss, A., Mananakas, C., Ha, O., Sedlmayer, F., Szabo, P. L., Fischer, I., Fichtinger, P., Podesser, B. K., Eriksson, M. et al. (2019). Endothelial progerin expression causes cardiovascular pathology through an impaired mechaensopone. J. Clin. Invest. 129, 531-545. doi:10.1172/JCI112129

Oliveri, L. J., Kellman, P., Spurney, C. F., Hahn, H. S., Wong, B. L., Lorenz, J. N., Wenisch, A. S. and Levin, J. G. (2019). PDE6 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. J. Clin. Invest. 129, 2131-2133. doi:10.1172/JCI132571

Pieske, B., Kretschmann, B., Meyer, M., Holubarsch, C., Weirich, J., Posival, H., Pieske, B., Kretschmann, B., Meyer, M., Holubarsch, C., Weirich, J., Posival, H., Bocza, D., S2-S6. (2006). Dystrophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol. 290, H2373-H2378. doi:10.1152/ajpheart.00484.2005

Quinlan, J. G., Hahn, H. B., Wong, B. L., Lorenz, J. N., Wenisch, A. S. and Levin, J. G. (2019). Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul. Disord. 13, 491-496. doi:10.1016/j.nmd.2014.04.007

Rubi, L., Todt, H., Kubista, H., Koenig, X. and Hilker, K. (2018). Calcium current properties in dystrophin-deficient ventricular cardiomyocytes from aged mdx mice. PLoS ONE 13, e0206158. doi:10.1371/journal.pone.0206158

Russo, V., Papa, A. A., Williams, E. A., Rago, A., Palladino, A., Polliaro, L. and Nigo, G. (2018). ACE inhibition to slow progression of myocardial fibrosis in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 71, A14-A23. doi:10.1016/j.jacc.2016.06.070

James, K. A., Grabli, D., Riddall, I., Caiazza, A. S., Mourani, P. M., Ciafaloni, E., Cunniff, C., Donnelly, J., Oleszek, J. et al. (2020). Left ventricular dysfunction in Duchenne muscular dystrophy. Cardiol. Young 30, 171-176. doi:10.1016/j.yycj.2019.10.019

Janssen, P. M. L., Hiranandani, N., Mays, T. A. and Raeford, J. A. (2005). Utricular contraction cardiac function dysfunction in mice and dystrophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol. 289, H2373-H2378. doi:10.1152/ajpheart.00484.2005
